Day One Biopharmaceuticals, Inc.
NASDAQ:DAWN
13.79 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.383 | 0.531 | 0.199 | 0.155 | 0 |
| Gross Profit
| -0.383 | -0.531 | -0.199 | -0.155 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 130.521 | 85.618 | 43.584 | 9.1 | 13.899 |
| General & Administrative Expenses
| 75.543 | 61.291 | 29.159 | 4.682 | 1.006 |
| Selling & Marketing Expenses
| -0.383 | 0 | 0 | 0 | 0 |
| SG&A
| 75.16 | 61.291 | 29.159 | 4.682 | 1.006 |
| Other Expenses
| 0 | -0.018 | -0.015 | -0.031 | -0.002 |
| Operating Expenses
| 205.681 | 146.909 | 72.743 | 13.782 | 14.905 |
| Operating Income
| -206.064 | -146.909 | -72.743 | -13.782 | -14.905 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 17.147 | 4.728 | -0.011 | -30.061 | -2.079 |
| Income Before Tax
| -188.917 | -142.181 | -72.754 | -43.843 | -16.984 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -10.005 | -2.312 | -3.337 | -2.273 |
| Net Income
| -188.917 | -132.176 | -70.442 | -40.506 | -14.711 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| EPS
| -2.37 | -2.02 | -1.14 | -0.65 | -0.24 |
| EPS Diluted
| -2.37 | -2.02 | -1.14 | -0.65 | -0.24 |
| EBITDA
| -205.681 | -146.909 | -72.743 | -13.658 | -14.907 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 |